Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells
CompletedPhase 3NCT01833585
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine the safety and efficacy of G-CSF-mobilized autologous peripheral blood mononuclear cell injection to ischemic limbs of patients with critical limb ischemia.
Study details
- Official title
- Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells
- Conditions
- Critical Limb Ischemia
- Atherosclerosis
- Ischemic Ulcer
- Gangrene
- Interventions
- Biological: Peripheral blood mononuclear cell
- Sponsor
- Mahidol University
- Start date
- 2013-04
- Primary completion
- 2017-12
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Thailand
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with critical limb ischemia confirmed by toe pressure, ABI, TCOM * Levels of arterial occlusion are femoropopliteal or tibioperoneal occlusion * Poor distal artery runoff * Age 18-70 year Exclusion Criteria: * Planned for major amputation within 4 weeks * Receive blood component within 4 weeks * Acute myocardial infarction * severe valvular heart disease * renal failure * liver failure * Cancer * Hypercoagulable state * Severe infection * Pregnancy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01833585